Proteins and Peptides

21 Sep 2018 Mylan and Biocon Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim
21 Sep 2018 Protalix BioTherapeutics Reports Positive Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease
21 Sep 2018 Sandoz receives positive CHMP opinion for proposed biosimilar pegfilgrastim
21 Sep 2018 Bayer receives positive CHMP opinion for its hemophilia A treatment BAY94-9027
21 Sep 2018 Novo Nordisk - Oral semaglutide demonstrates greater reductions in HbA1c and body weight and comparable number of adverse events vs dulaglutide in Japanese people with type 2 diabetes
21 Sep 2018 Cinfa Biotech receives positive CHMP opinion for Pelmeg(R) (pegfilgrastim), a proposed biosimilar to Neulasta(R)
20 Sep 2018 ERYTECH Announces Enrollment of First Patients in Phase 3 Clinical Trial Evaluating Eryaspase for the Treatment of Second Line Pancreatic Cancer
19 Sep 2018 BioAegis Therapeutics Enrolls First Patients in Phase 1b/2a Community-Acquired Pneumonia Study and Raises $4 MM in Equity Round
18 Sep 2018 Zealand Pharma achieves primary and key secondary endpoints in pivotal Phase 3 trial with dasiglucagon for severe hypoglycemia
17 Sep 2018 Oramed Receives FDA Clearance for IND Application for Its Oral GLP-1 Analog Capsule
17 Sep 2018 Aeglea BioTherapeutics Announces Oral Presentation of Preclinical Data on New Pipeline Therapeutic for Cystinuria at 2018 American Society of Nephrology
15 Sep 2018 Allergan Announces Results of Higher Dose BOTOX® Cosmetic (onabotulinumtoxinA) for the Treatment of Moderate to Severe Glabellar Lines
12 Sep 2018 Shire granted EU marketing authorization for Veyvondi® [vonicog alfa, recombinant von willebrand factor] for adults with von Willebrand disease
10 Sep 2018 Alkermes Initiates Clinical Evaluation of Novel Immuno-Oncology Drug Candidate ALKS 4230 in Combination With PD-1 Inhibitor Pembrolizumab
10 Sep 2018 Amicus Therapeutics Announces Regulatory and Clinical Updates for AT-GAA in Pompe Disease
06 Sep 2018 PvP Biologics Announces First-in-Human Clinical Trials for a Novel Therapeutic for Celiac Disease
06 Sep 2018 ContraFect Completes Enrollment in Phase 2 Clinical Trial Evaluating CF-301 (exebacase) in Patients with Staphylococcus Aureus Bacteremia
05 Sep 2018 Thrombolytic Science Initiates Phase 2 Clinical Trial of its Novel Treatment Regimen for Ischemic Stroke
04 Sep 2018 Aeglea BioTherapeutics Announces Positive Interim Clinical Data and Completion of Enrollment for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency
30 Aug 2018 Bayer Receives FDA Approval for Jivi®, New Hemophilia A Treatment With Step-Wise Prophylaxis Dosing Regimen
30 Aug 2018 European Commission approves new easy-to-use, once-weekly Bydureon BCise device for patients with type-2 diabetes
28 Aug 2018 Ultragenyx Announces Approval of Mepsevii™ (vestronidase alfa) in Europe for the Treatment of Mucopolysaccharidosis VII
27 Aug 2018 Amgen Submits Supplemental New Drug Application For KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone
26 Aug 2018 Ozempic® consistently reduced the risk of major cardiovascular events across type 2 diabetes populations at high CV risk regardless of prior CV events at baseline
23 Aug 2018 Dompé receives FDA approval of Oxervate™ eye drops (cenegermin-bkbj ophthalmic solution), first-in-class recombinant human nerve growth factor with potential to completely heal rare neurotrophic keratitis

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up